Y-Mabs Therapeutics Inc (NASDAQ: YMAB) has seen a decline in its stock price by -4.17 in relation to its previous close of 10.54. However, the company has experienced a -12.86% decline in its stock price over the last five trading sessions. zacks.com reported 2024-11-08 that Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago.
Is It Worth Investing in Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Right Now?
YMAB has 36-month beta value of 0.62. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for YMAB is 37.18M, and currently, short sellers hold a 10.80% ratio of that float. The average trading volume of YMAB on November 22, 2024 was 261.70K shares.
YMAB’s Market Performance
The stock of Y-Mabs Therapeutics Inc (YMAB) has seen a -12.86% decrease in the past week, with a -32.08% drop in the past month, and a -26.49% fall in the past quarter. The volatility ratio for the week is 8.23%, and the volatility levels for the past 30 days are at 7.06% for YMAB. The simple moving average for the past 20 days is -25.46% for YMAB’s stock, with a -26.55% simple moving average for the past 200 days.
Analysts’ Opinion of YMAB
Many brokerage firms have already submitted their reports for YMAB stocks, with Oppenheimer repeating the rating for YMAB by listing it as a “Outperform.” The predicted price for YMAB in the upcoming period, according to Oppenheimer is $23 based on the research report published on November 18, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see YMAB reach a price target of $20. The rating they have provided for YMAB stocks is “Overweight” according to the report published on August 16th, 2024.
Truist gave a rating of “Buy” to YMAB, setting the target price at $21 in the report published on June 28th of the current year.
YMAB Trading at -26.58% from the 50-Day Moving Average
After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.67% of loss for the given period.
Volatility was left at 7.06%, however, over the last 30 days, the volatility rate increased by 8.23%, as shares sank -31.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.72% lower at present.
During the last 5 trading sessions, YMAB fell by -12.86%, which changed the moving average for the period of 200-days by -22.61% in comparison to the 20-day moving average, which settled at $13.55. In addition, Y-Mabs Therapeutics Inc saw 48.09% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at YMAB starting from Gad Thomas, who sale 65,000 shares at the price of $13.47 back on Sep 13 ’24. After this action, Gad Thomas now owns 97,681 shares of Y-Mabs Therapeutics Inc, valued at $875,550 using the latest closing price.
Gad Thomas, the CHIEF BUSINESS OFFICER of Y-Mabs Therapeutics Inc, sale 30,000 shares at $12.97 during a trade that took place back on Sep 16 ’24, which means that Gad Thomas is holding 67,681 shares at $389,100 based on the most recent closing price.
Stock Fundamentals for YMAB
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.89 for the gross margin
The net margin for Y-Mabs Therapeutics Inc stands at -0.28. The total capital return value is set at -0.3. Equity return is now at value -24.78, with -19.11 for asset returns.
Currently, EBITDA for the company is -25.67 million with net debt to EBITDA at 2.41. When we switch over and look at the enterprise to sales, we see a ratio of 4.56. The receivables turnover for the company is 4.25for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.92.
Conclusion
To put it simply, Y-Mabs Therapeutics Inc (YMAB) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
